← Leaderboards
Munir Tanas
University Of Iowa
$1,871,722
Attributed
$1,871,722
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $414.3K · FY2017–25$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,871,722 · 1
VA$0 · 1
By mechanism
R01$1,871,722 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Targeted Treatment”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Leonard Freedman · Leidos Biomedical Research, Inc.$66,755,704
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
Targeted TreatmentGenetic TranscriptionMouse ModelLifeInnovationIn VivoRegulationOncogenicTranscription CoactivatorMalignant NeoplasmsPathway InteractionsOncoproteinsSarcomaPlayTranscriptome SequencingCoupledXenograft ProcedureTherapeutic TargetMedicalCell LineHistologicNeoplasm MetastasisTranscriptomePrograms
Grant awards (15)
Upstream regulation of TAZ and YAP in sarcomas: Towards combinatorial therapytargeting the Hippo pathway$0
I01 · FY2025 · VA · contact PI
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex$330,792
R01 · FY2024 · CA · contact PI
Upstream regulation of TAZ and YAP in sarcomas: Towards combinatorial therapytargeting the Hippo pathway$0
I01 · FY2024 · VA · contact PI
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex$341,237
R01 · FY2023 · CA · contact PI
Upstream regulation of TAZ and YAP in sarcomas: Towards combinatorial therapytargeting the Hippo pathway$0
I01 · FY2023 · VA · contact PI
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex$348,201
R01 · FY2022 · CA · contact PI
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex$66,069
R01 · FY2022 · CA · contact PI
Upstream regulation of TAZ and YAP in sarcomas: Towards combinatorial therapytargeting the Hippo pathway$0
I01 · FY2022 · VA · contact PI
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex$414,270
R01 · FY2021 · CA · contact PI
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex$348,201
R01 · FY2020 · CA · contact PI
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex$22,952
R01 · FY2020 · CA · contact PI
Upstream regulation of TAZ and YAP in sarcomas: towards combinatorial therapy targeting the Hippo Pathway$0
I01 · FY2020 · VA · contact PI
Upstream regulation of TAZ and YAP in sarcomas: towards combinatorial therapy targeting the Hippo Pathway$0
I01 · FY2019 · VA · contact PI
Upstream regulation of TAZ and YAP in sarcomas: towards combinatorial therapy targeting the Hippo Pathway$0
I01 · FY2018 · VA · contact PI
Upstream regulation of TAZ and YAP in sarcomas: towards combinatorial therapy targeting the Hippo Pathway$0
I01 · FY2017 · VA · contact PI